Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer
NCT ID: NCT03123263
Last Updated: 2019-09-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2017-04-11
2019-02-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigating the Long-term Cardiac Sequelae of Trastuzumab Therapy
NCT05019365
Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients
NCT00806507
Effect of Concomitant Radiotherapy and Trastuzumab on Cardiotoxicity of Patients Treated for Early Breast Cancer
NCT01572883
Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab
NCT04961307
Molecular Profiling After Neoadjuvant Chemotherapy for Triple-negative Breast Cancer
NCT04362462
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Transtuzumab affects cardiac function and potential benefits in decreasing cancer recurrence have to be balanced against short and long term toxicity.
We have previously identified a high prevalence of metabolic syndrome and type II diabetes mellitus in our patients with breast cancer. These patients may be particularly susceptible to cardiotoxic effects of transtuzumab based therapy.
Aim of this study is to assess the changes in the cardiac function of women who are undergoing transtuzumab based therapy for early stage breast cancer.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Her2+
Exclusion Criteria
18 Years
90 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Texas Tech University Health Sciences Center, El Paso
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sumit Gaur
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sumit Gaur
Role: PRINCIPAL_INVESTIGATOR
TTUHSC El Paso
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ttuhsc
El Paso, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E17080
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.